Article Text

Download PDFPDF
BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs
  1. C W Wong1,
  2. Y S Fan1,
  3. T L Chan1,
  4. A S W Chan1,
  5. L C Ho2,
  6. T K F Ma3,
  7. the Cancer Genome Project4,
  8. S T Yuen1,
  9. S Y Leung1
  1. 1Department of Pathology, University of Hong Kong, Queen Mary Hospital, Hong Kong
  2. 2Department of Pathology, Queen Elizabeth Hospital, Hong Kong
  3. 3Department of Pathology, Alice Ho Mui Ling Nethersole Hospital, Hong Kong
  4. 4Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK
  1. Correspondence to:
 Dr S Y Leung
 Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong; suetyihkucc.hku.hk

Abstract

Background: Malignant melanoma arising from different body compartments may be associated with differing aetiological factors and clinical behaviour, and may manifest diverse molecular genetic profiles. Although many studies have focused on cutaneous melanoma, little is known of mucosal and other types of melanoma. In particular, malignant melanoma of soft parts is different from other melanomas in many respects, yet manifests a common melanocytic differentiation. Mutation of BRAF is now known to be common in cutaneous melanomas, and raises possible new therapeutic options of anti-RAF treatment for these patients. Few data are available for non-cutaneous melanomas.

Aims: To study the incidence of BRAF and NRAS mutations in melanomas arising in diverse internal organs.

Methods: Fifty one melanomas from various internal organs were investigated for BRAF and NRAS mutation by direct DNA sequencing.

Results: BRAF and NRAS mutations were found in two and five mucosal melanomas arising from the aerodigestive and female genital tracts (n = 36). Their occurrence is mutually exclusive, giving a combined mutation incidence rate of 19.4% in mucosal melanomas. Both BRAF and NRAS mutations were absent in malignant melanoma of soft parts (n = 7). BRAF mutation was also absent in uveal melanoma (n = 6), but was seen in two of five cutaneous melanomas. The incidence of BRAF or combined BRAF/NRAS mutations in all non-cutaneous groups was significantly lower than published rates for cutaneous melanomas.

Conclusion: Each melanoma subtype may have a unique oncogenetic pathway of tumour development, and only a small fraction of non-cutaneous melanomas may benefit from anti-RAF treatment.

  • MAPK, mitogen activated protein kinase
  • PCR, polymerase chain reaction
  • UV, ultraviolet
  • BRAF
  • NRAS
  • mucosal melanoma
  • malignant melanoma of soft parts

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interest: Members of the Cancer Genome Project are inventors of a patent relating to the development of BRAF for treatment and diagnostics